A vision for Perlstein Lab

A vision for Perlstein Lab

Today’s post will focus on the vision for PLab. Let’s start with a basic statistical concept- long tail distribution. While this form of frequency distribution has been around since the 1940’s, it gained prominence in fields outside of insurance and...
The great orphan drug price debate

The great orphan drug price debate

This post is written by Kiran Singh, Data Guru @PLab. The third and final installment in our series on orphan drugs for monogenic diseases looks into potential causes for the sharp rise in their prices. It’s not readily apparent why this is happening. If we look at...
Biologics and you

Biologics and you

This post is written by Kiran Singh, Data Guru @PLab. In our last post we talked specifically about orphan drugs that are small molecules. In this post I’ll address the orphan drugs that are biologics. They behave differently: There’s a possible increase in...
Orphan drug prices and approvals

Orphan drug prices and approvals

This post is written by Kiran Singh, Data Guru @PLab. This post kicks off a series about drug prices in the orphan drug space. We initially wanted to get a sense of orphan drug price trends over the last 30 years — since the passage of the Orphan Drug Act of...
Translate »